These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 17890953

  • 1. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A, Wiman B, Schulman S.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [Abstract] [Full Text] [Related]

  • 2. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D, Kremplewska-Nalezyta E, Gadomska G, Zastawna E, Michalski A, Drewniak W.
    Med Sci Monit; 2000 Oct; 6(4):684-91. PubMed ID: 11208392
    [Abstract] [Full Text] [Related]

  • 3. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K, Szaflarska-Popławska A, Dymek G, Kotschy M.
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [Abstract] [Full Text] [Related]

  • 4. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD, Gram J, Jespersen J.
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [Abstract] [Full Text] [Related]

  • 5. Plasminogen activator inhibitor type 1 deficiency.
    Mehta R, Shapiro AD.
    Haemophilia; 2008 Nov; 14(6):1255-60. PubMed ID: 19141166
    [Abstract] [Full Text] [Related]

  • 6. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E, Dziedziczko A, Rość D.
    Med Sci Monit; 2000 Nov; 6(1):103-7. PubMed ID: 11208294
    [Abstract] [Full Text] [Related]

  • 7. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y, Okumura KI, Yoshida N, Tayama K, Takemura Y, Inukai T.
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [Abstract] [Full Text] [Related]

  • 8. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
    Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C.
    Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
    [Abstract] [Full Text] [Related]

  • 9. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC.
    Thromb Res; 2008 Aug; 121(5):675-80. PubMed ID: 17870147
    [Abstract] [Full Text] [Related]

  • 10. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG, Bots ML, Haverkate F, Meyer P, Hofman A, Grobbee DE, Kluft C.
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [Abstract] [Full Text] [Related]

  • 11. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
    Walter T, Szabo S, Kazmaier S, Suselbeck T, Borggrefe M, Hoffmeister HM.
    Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
    [Abstract] [Full Text] [Related]

  • 12. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
    Mavrommatis AC, Theodoridis T, Economou M, Kotanidou A, El Ali M, Christopoulou-Kokkinou V, Zakynthinos SG.
    Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
    [Abstract] [Full Text] [Related]

  • 13. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
    Mutoh S, Kobayashi M, Hirata J, Itoh N, Maki M, Komatsu Y, Yoshida A, Sasa H, Kuroda K, Kikuchi Y.
    Agents Actions Suppl; 1992 Dec; 38 ( Pt 2)():320-9. PubMed ID: 1462839
    [Abstract] [Full Text] [Related]

  • 14. Fibrinolytic activity in multiple myeloma.
    Yağci M, Sucak GT, Haznedar R.
    Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202
    [Abstract] [Full Text] [Related]

  • 15. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
    Sørensen JV.
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
    [Abstract] [Full Text] [Related]

  • 16. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
    Philippé J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D.
    Thromb Haemost; 1991 Mar 04; 65(3):291-5. PubMed ID: 1904655
    [Abstract] [Full Text] [Related]

  • 17. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H, Mori Y, Okabayashi K, Gabazza EC, Kushiya F, Watanabe M, Nishikawa M, Shiku H, Nobori T.
    Am J Hematol; 2003 Jan 04; 72(1):1-7. PubMed ID: 12508260
    [Abstract] [Full Text] [Related]

  • 18. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I, Zietek Z, Kotschy M, Rość D, Tyloch F.
    Pol Tyg Lek; 1996 Feb 04; 51(6-9):91-3. PubMed ID: 8756741
    [Abstract] [Full Text] [Related]

  • 19. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer.
    Nanninga PB, van Teunenbroek A, Veenhof CH, Büller HR, ten Cate JW.
    Thromb Haemost; 1990 Nov 30; 64(3):361-4. PubMed ID: 1710832
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.